PT Indoritel Makmur Internasional Tbk. (IDX:DNET)

Ligand Pharmaceuticals Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,531,952	1,427,731	1,390,105	1,138,330	844,412	488,888
Revenue Growth (YoY)	8.11%	2.71%	22.12%	34.81%	72.72%	89.64%
Cost of Revenue	65,973	65,973	38,983	48,968	28,321	23,303
Gross Profit	1,465,979	1,361,758	1,351,122	1,089,362	816,091	465,585
Selling, General & Admin	1,204,842	1,107,561	899,988	718,218	538,168	412,915
Other Operating Expenses	-13,404	4,248	6,990	-1,955	11,516	13,213
Operating Expenses	1,191,438	1,111,809	906,978	716,263	549,684	426,128
Operating Income	274,541	249,949	444,144	373,099	266,407	39,457
Interest Expense	-550,837	-553,085	-567,311	-529,764	-584,039	-574,504
Interest & Investment Income	532,166	532,166	488,998	539,458	587,287	532,699
Earnings From Equity Investments	1,019,231	914,150	479,474	1,012,022	732,287	346,101
Other Non Operating Income (Expenses)	-43,389	-4	-57	-51	-42	-38
EBT Excluding Unusual Items	1,231,712	1,143,176	845,248	1,394,764	1,001,900	343,715
Gain (Loss) on Sale of Investments	2,187	2,187	11,632	1,746	-11,679	-188
Gain (Loss) on Sale of Assets	-	-	-65	72	72	29
Asset Writedown	-	-	-	-	-	-155
Pretax Income	1,233,899	1,145,363	856,815	1,396,582	990,293	343,401
Income Tax Expense	51,473	53,753	69,973	38,832	21,820	16,348
Earnings From Continuing Operations	1,182,426	1,091,610	786,842	1,357,750	968,473	327,053
Minority Interest in Earnings	-14,592	-19,539	-65,802	-68,127	-41,556	1,775
Net Income	1,167,834	1,072,071	721,040	1,289,623	926,917	328,828
Net Income to Common	1,167,834	1,072,071	721,040	1,289,623	926,917	328,828
Net Income Growth	65.31%	48.68%	-44.09%	39.13%	181.89%	-37.13%
Shares Outstanding (Basic)	14,184	14,184	14,184	14,184	14,184	14,184
Shares Outstanding (Diluted)	14,184	14,184	14,184	14,184	14,184	14,184
EPS (Basic)	82.33	75.58	50.83	90.92	65.35	23.18
EPS (Diluted)	82.33	75.58	50.83	90.92	65.35	23.18
EPS Growth	65.29%	48.68%	-44.09%	39.13%	181.89%	-37.13%
Free Cash Flow	-686,249	-727,800	-426,984	-517,439	-510,486	-809,598
Free Cash Flow Per Share	-48.38	-51.31	-30.10	-36.48	-35.99	-57.08
Gross Margin	95.69%	95.38%	97.20%	95.70%	96.65%	95.23%
Operating Margin	17.92%	17.51%	31.95%	32.78%	31.55%	8.07%
Profit Margin	76.23%	75.09%	51.87%	113.29%	109.77%	67.26%
Free Cash Flow Margin	-44.80%	-50.98%	-30.72%	-45.46%	-60.46%	-165.60%
EBITDA	893,037	827,128	909,804	734,842	540,235	242,969
EBITDA Margin	58.29%	57.93%	65.45%	64.55%	63.98%	49.70%
D&A For EBITDA	618,496	577,179	465,660	361,743	273,828	203,512
EBIT	274,541	249,949	444,144	373,099	266,407	39,457
EBIT Margin	17.92%	17.51%	31.95%	32.78%	31.55%	8.07%
Effective Tax Rate	4.17%	4.69%	8.17%	2.78%	2.20%	4.76%
Advertising Expenses	-	-	-	-	-	180

Source: S&P Global Market Intelligence. Standard template. Financial Sources.